Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.0600 -0.0500 (-4.50%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.1000 +0.0400 (+3.77%) 19:59 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0300
Day High
1.1000
Open 1.1000
Previous Close 1.1100 1.1100
Volume 256,400 256,400
Avg Vol 333,180 333,180
Stochastic %K 90.34% 90.34%
Weighted Alpha -77.23 -77.23
5-Day Change +0.1851 (+21.16%) +0.1851 (+21.16%)
52-Week Range 0.3975 - 5.4700 0.3975 - 5.4700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,481
  • Shares Outstanding, K 14,000
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,760 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 2.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.71
  • Number of Estimates 1
  • High Estimate -0.71
  • Low Estimate -0.71
  • Prior Year -2.02
  • Growth Rate Est. (year over year) +64.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6900 +53.62%
on 04/09/25
Period Open: 1.1500
1.1500 -7.83%
on 03/26/25
-0.0900 (-7.83%)
since 03/25/25
3-Month
0.3975 +166.67%
on 02/12/25
Period Open: 1.7000
3.6499 -70.96%
on 02/13/25
-0.6400 (-37.65%)
since 01/24/25
52-Week
0.3975 +166.67%
on 02/12/25
Period Open: 4.3082
5.4700 -80.62%
on 05/01/24
-3.2482 (-75.40%)
since 04/25/24

Most Recent Stories

More News
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

MBRX : 1.0600 (-4.50%)
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

MBRX : 1.0600 (-4.50%)
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

MBRX : 1.0600 (-4.50%)
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

MBRX : 1.0600 (-4.50%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

- Access video webcasts from all participating companies here

AIM : 0.0949 (-19.37%)
SONN : 1.3700 (+0.74%)
MBRX : 1.0600 (-4.50%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.3600 (-5.56%)
AIM : 0.0949 (-19.37%)
PEPG : 1.5300 (-8.93%)
AEON : 0.4304 (-6.43%)
MBRX : 1.0600 (-4.50%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 37.20 (-1.30%)
ADMA : 21.86 (-2.10%)
EXEL : 37.43 (+0.59%)
GLYC : 0.2610 (+4.11%)
MBRX : 1.0600 (-4.50%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

AREC : 1.0400 (-13.33%)
CNSP : 1.0900 (+4.81%)
EVFM : 0.0090 (-1.10%)
XBIO : 2.79 (+3.61%)
PALI : 0.7200 (-2.11%)
NVNO : 2.73 (+0.18%)
GRI : 1.8200 (+8.98%)
MBRX : 1.0600 (-4.50%)
Moleculin to Participate in the Virtual Investor Ask the CEO Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 1.0600 (-4.50%)
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 1.0600 (-4.50%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 1.1667
2nd Resistance Point 1.1333
1st Resistance Point 1.0967
Last Price 1.0600
1st Support Level 1.0267
2nd Support Level 0.9933
3rd Support Level 0.9567

See More

52-Week High 5.4700
Fibonacci 61.8% 3.5323
Fibonacci 50% 2.9337
Fibonacci 38.2% 2.3352
Last Price 1.0600
52-Week Low 0.3975

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective